Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499 in Hepatic Impairment and Normal Hepatic Function
NCT05917938Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Hormonal Peptides
- Countries
- 3
01
Overview
Phase 1, open-label trial of nn9500 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH), sponsored by Novo Nordisk. Primary endpoint: Area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity at Day 36. Started Jul 2023; status: completed.
02
Drugs
nn9500
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05917938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917938.